Review of insomnia pharmacotherapy options for the elderly: Implications for managed care

Population Health Management

Volumn 12, Issue 6, 2009, Pages 317-323

  Taylor, Scott R ^a   Weiss, Jack S ^b  

^a GEISINGER HEALTH SYSTEM   (United States)

^b United Health Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; MELATONIN; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; QUAZEPAM; RAMELTEON; SEDATIVE AGENT; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM;

AGED; ANTEROGRADE AMNESIA; CHRONIC DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONFUSION; COST EFFECTIVENESS ANALYSIS; DAYTIME FATIGUE; DIZZINESS; DOCTOR PATIENT RELATION; DROWSINESS; DRUG ABUSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FALLING; FATIGUE; FOOD AND DRUG ADMINISTRATION; FRACTURE; HEADACHE; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; INSOMNIA; LIVER TOXICITY; MANAGED CARE; MEMORY DISORDER; MOTOR DYSFUNCTION; PRACTICE GUIDELINE; PREVALENCE; REBOUND INSOMNIA; RECOMMENDED DRUG DOSE; RELAXATION TRAINING; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP DISRUPTION; SLEEP WAKING CYCLE; SOMNOLENCE; WITHDRAWAL SYNDROME;

AGED; COST OF ILLNESS; DRUG THERAPY; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; MANAGED CARE PROGRAMS; SLEEP INITIATION AND MAINTENANCE DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73949112822     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2008.0047     Document Type: Review

References (60)

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42:225-232.
2. US Department of Health and Human Services, National Institutes of Health. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. Available at: http://www.consensus .nih.gov/2005/2005InsomniaSOS026html.htm. Accessed May 14, 2008.
3. Bridges J. The health plan perspective of insomnia. Managed Care 2006;15:13-14.
4. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39:411-418.
5. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158: 1099-1107.
6. Avidan AY. Insomnia in the geriatric patient. Clin Cornerstone 2003;5:51-60.
7. Vorona RD, Winn MP, Babineau TW, Eng BP, Feldman HR, Ware JC. Overweight and obese patients in a primary care population report less sleep than patients with a normal body mass index. Arch Intern Med 2005;165:25-30.
8. Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and Management of Chronic Insomnia in Adults. AHRQ Publication No. 05-E021-2. Available at www.ahrq.gov/ downloads/pub/evidence/pdf/insomnia/insomnia.pdf. Accessed May 27, 2008.
9. Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 2005;53:S264-S271.
10. Martin J, Shochat T, Ancoli-Israel S. Assessment and treatment of sleep disturbances in older adults. Clin Psychol Rev 2000;20:783-805.
11. Kamel NS, Gamack JK. Insomnia in the elderly: Cause, approach, and treatment. Am J Med 2006;119:463-469.
12. Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16:873-897.
13. Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 1991;4:204-210.
14. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: A 12-year followup study of a middle-aged Swedish population. J Intern Med 2002;251:207-216.
15. Manabe K, Matsui T, Yamaya M, et al. Sleep patterns and mortality among elderly patients in a geriatric hospital. Gerontology 2000;46:318-322.
16. Mallon L, Broman JE, Hetta J. Relationship between insomnia, depression, and mortality: A 12-year follow-up of older adults in the community. Int Psychogeriatr 2000;12: 295-306.
17. Morin AK, Jarvis CI, Lynch AM. Therapeutic options for sleep-maintenance and sleep-onset insomnia. Pharmacotherapy 2007;27:89-110.
18. Erman MK. Therapeutic options in the treatment of insomnia. J Clin Psychiatry 2005;66:18-23.
19. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician 2007;76:517-526.
20. ProSom (estazolam tablets) [prescribing information]. North Chicago, IL: Abbott Laboratories U.S.; 2004.
21. Dalmane (flurazepam) clinical pharmacology. Aliso Viegjo, CA: Valeant Pharmaceuticals North America; 2007 Available at: www.rxlist.com/cgi/generic/ fluraz-cp.htm. Accessed September 9, 2008.
22. Dalmane. Available at http://www.rxlist.com/ccgi/generic/ fluraz-ids.htm. Accessed September 9, 2008.
23. Doral (quazepam tablets) clinical pharmacology. Union City, CA: Questcor Pharmaceuticals, Inc.; 2007.
24. Questcor Pharmaceuticals. Doral (quazepam tablets) Indications and Dosage. Union City, CA: Questcor Pharmaceuticals, Inc.; 2007.
25. Restoril (temazepam capsules) [package insert]. St Louis, MO: Mallinckrodt Inc.; 2007.
26. Halcion (triazolam tablets) [prescribing information and medication guide]. New York, NY: Pharmacia & Upjohn Company, Division of Pfizer Inc.; 2008.
27. Lunesta (eszopiclone tablets) [package insert]. Marlborough, MA: Sepracor Inc.; 2008.
28. Ambien (zolpidem tartrate tablets) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2007.
29. Ambien CR (zolpidem tartrate extended-release tablets) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2008.
30. Sonata (zaleplon caplets) [prescribing information]. Bristol, TN: King Pharmaceuticals, Inc.; 2007.
31. Rozerem (ramelteon tablets) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2006.
32. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303-3307.
33. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-1065.
34. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-1350.
35. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-233.
36. Leppik IE, Roth-Schecter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev Res 1997;40:230-238.
37. Walsh JK, Soubrane C, Roth T, ZOLEDERLY Study Group. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57.
38. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-120.
39. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15:704-712.
40. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-727.
41. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3- period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005-1014.
42. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006;7:312-318.
43. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-2724.
44. Perri M III, Menon AM, Deshpande AD, et al. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother 2005;39:405-411.
45. Rigler SK, Perera S, Jachna C, Shireman TI, Eng M. Comparison of the association between disease burden and inappropriate medication use across three cohorts of older adults. Am J Geriatr Pharmacother 2004;2:239-247.
46. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332: 767-773.
47. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30-39.
48. Herings RM, Stricker BH, de BA, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995;155:1801-1807.
49. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158:892-898.
50. Allain H, tue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005;22:749-765.
51. Allain H, tue-Ferrer D, Tarral A, Gandon JM. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75mg and lormetazepam 1mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003;59:179-188.
52. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001;49:1685-1690.
53. Neubauer DN. State-of-the-art sleep management. Managed Care 2006;15:6-12.
54. Wang-Weigand S, Zammit G, Peng X. Placebo-controlled, double-blind trial examining the effects of ramelteon vs placebo with zolpidem as a reference on balance in older adults after middle-of-the-night awakening. Presented at: 2007 American Psychiatric Association Annual Meeting; May 19-24, 2007; San Diego, CA.
55. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005;66:31-41.
56. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: A review of case reports and epidemiological data. Addiction 2003;98:1371-1378.
57. American Association for Geriatric Psychiatry. Geriatrics and mental health - the facts. Available at: http://www .aagponline.org/prof/facts-mh.asp. Accessed September 4, 2008.
58. Johnson MW, Suess PE, Griffiths RR. Ramelteon: A novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149-1157.
59. Tramontozzi AT, Chan MW, Leung PS, et al. Cost-benefit analysis of zolpidem 10mg versus ramelteon 8mg in adults aged 18 to 65 years with insomnia in the United States over a five-week period from a societal perspective. Abstract presented at: ASHP Midyear Clinical Meeting; December 3-7, 2006; Anaheim, CA.
60. Patel M, Sterback M, Curran EA, Verlizzo B, Foustellis M. Cost-effectiveness of eszopiclone versus ramelteon in adult patients with chronic insomnia over a one month period from a third party perspective. Abstract presented at: ASHP Midyear Clinical Meeting; December 3-7, 2006; Anaheim, CA.